A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

  The company Imago Biosciences, which focuses on developing anti-cancer therapies, is carrying out a Phase 1/2a clinical study of an investigational drug called IMG-7289 as a potential treatment for…

Continue Reading A Study of an Investigational Acute Myeloid Leukaemia and Myelodysplastic Syndrome Drug Has Completed Enrolment

Welcome AAMDS, a New Patient Worthy Advocacy Partner!

We're happy to introduce a new partner to Patient Worthy's mission of advocating for rare disease patients! The Aplastic Anemia and MDS International Foundation (AAMDS) supports, connects and educates patients, caregivers…

Continue Reading Welcome AAMDS, a New Patient Worthy Advocacy Partner!
A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes
Source: Pixabay

A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes

A press release from Aprea Theraputics has just announced the results of a Phase II clinical trial of the drug APR-246 in patients with myelodysplastic syndromes (a group of blood…

Continue Reading A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes
This Drug May Reduce Your Dependence on Transfusions
Source: https://pixabay.com/en/blood-medical-attempts-tube-1291132/

This Drug May Reduce Your Dependence on Transfusions

Celgene Corporation, partnered with Acceleron Pharma Inc., announced at the beginning of this month that target enrollment of myelodysplastic syndromes (MDS) and beta thalassemia patients for the MEDALIST and BELIEVE…

Continue Reading This Drug May Reduce Your Dependence on Transfusions